I1. Utilisation of health care systems

How can we find good candidate molecules for further drug development and discovery? Drug development is expensive and affects health care strategies and costs. Graphical display, association measures and cross-tables are tools of the trade of modellers - but do we truly understand their links? How can aggregate data analytic methods be developed further to better assess risk and intervention effects. How do the odds ratio and other measures relate? How best to evaluate the benefit of lab interventions to implement health and safety change is also considered.